Published in Can Respir J on October 04, 2011
The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes (2014) 0.87
Computational Modeling Predicts Simultaneous Targeting of Fibroblasts and Epithelial Cells Is Necessary for Treatment of Pulmonary Fibrosis. Front Pharmacol (2016) 0.80
Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. Patient Relat Outcome Meas (2016) 0.75
Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res (2017) 0.75
Standardisation of spirometry. Eur Respir J (2005) 48.20
ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med (2002) 31.79
The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care (1993) 27.05
The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care (1994) 19.87
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med (2000) 12.71
The St George's Respiratory Questionnaire. Respir Med (1991) 8.49
Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J (2005) 7.58
Standardisation of the measurement of lung volumes. Eur Respir J (2005) 7.48
High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2005) 7.20
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med (2004) 6.02
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2005) 5.83
A simple method of sample size calculation for linear and logistic regression. Stat Med (1998) 4.74
Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ (2000) 3.77
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 3.49
Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med (2003) 3.07
Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest (2006) 2.73
Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.71
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med (2008) 2.65
Assessment of health-related quality of life in patients with interstitial lung disease. Chest (1999) 2.21
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18
Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes (2005) 1.69
Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax (2005) 1.64
Electronic collection of health-related quality of life data: validity, time benefits, and patient preference. Qual Life Res (2001) 1.54
Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? Respir Med (2005) 1.51
Interpretation of quality of life scores from the St George's Respiratory Questionnaire. Eur Respir J (2002) 1.48
The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax (2009) 1.46
Reassessment of the classification of the severity in idiopathic pulmonary fibrosis using SF-36 questionnaire. Intern Med (2005) 1.45
Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with idiopathic pulmonary fibrosis. Chest (2000) 1.37
Health-related quality of life among patients with idiopathic pulmonary fibrosis. Chest (2005) 1.36
Normal values for the ratio of one-second forced expiratory volume to forced vital capacity. Am Rev Respir Dis (1973) 1.28
Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med (1998) 1.20
Health-related quality of life in patients with idiopathic pulmonary fibrosis--cross-sectional and longitudinal study. Intern Med (2007) 1.14
Quality of life of idiopathic pulmonary fibrosis patients. Eur Respir J (2001) 1.07
Attachment for automated single breath diffusing capacity measurement. Chest (1973) 0.87
Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J (2009) 0.80
International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2006) 4.95
Cellular markers of muscle atrophy in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol (2009) 1.26
Impact of extracorporeal life support on outcome in patients with idiopathic pulmonary arterial hypertension awaiting lung transplantation. J Heart Lung Transplant (2011) 1.16
Deciding about lung transplantation: informational needs of patients and support persons. Prog Transplant (2007) 0.85
Physical activity profile of lung transplant candidates with interstitial lung disease. J Cardiopulm Rehabil Prev (2013) 0.83
Recurrence of CMV Infection and the Effect of Prolonged Antivirals in Organ Transplant Recipients. Transplantation (2017) 0.76
Diagnosis of paracardiac castleman disease by dynamic gadolinium-enhanced first pass perfusion magnetic resonance imaging. Clin Med Case Rep (2008) 0.75